MELBOURNE, Australia, July 16, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an

Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeki

NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today released a Fla

Sales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pc

NEW YORK CITY, NEW YORK / ACCESS Newswire / March 5, 2026 / Emerging Growth Research today released

NEW YORK CITY, NY / ACCESS Newswire / January 22, 2026 / Emerging Growth Research today released a F

Sales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior comparative period (pcp

Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigati

New York, New York--(Newsfile Corp. - October 17, 2025) - Emerging Growth Research today announced t

Sales Highlights (unaudited): Global • Q1 sales AUD$2.0 million up 34% on prior comparative period (

Key Points Immuron submits Investigational new drug (IND) application to FDA for clinical developmen

Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced

MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) adv

Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior year June 2025 Qua

Highlights: Immuron on track to exceed A$7 million in Sales this financial year Uniformed Services U

Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highe

MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a

Sales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on p

Highlights: New Research Collaboration w ith Monash University One proposal will target Antimicrobia

Highlights: Travelan® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDA Travelan® (IMM-1